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S_mury Plasma level. plasma clearance, production rate and interconversions of oestrone and oestrone
sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy. Three additional
patients had the production rate of oestrone sulphate investigated. Plasma oestrone and oestrone sulphate
levels were reduced by a mean of 46% (P<O.05) and 71% (P<0.005) respectively. These alterations were due
to a combined action of aminoglutethimide inhibiting oestrogen production but also increasing oestrogen
metabolism. While oestrone and oestrone sulphate production rate was reduced by a mean of 31% (P<0.05)
and 41% (P<0.005) respectively, the plasma clearance rate of oestrone was found to be increased by a mean
of 30% (P<0.05), and the plasma clearance rate of oestrone sulphate was increased by a mean of 112%
during aminoglutethimide treatment. The fraction of oestrone sulphate converted into plasma oestrone was
reduced by 52% (P<0.05), the transfer of circulating oestrone into oestrone sulphate was non-significantly
reduced by a mean of 16%. The findings in this investigation show that aminoglutethimide treatment
influences oestrogen disposition by mechanisms unrelated to aromatase inhibition. The possibility that such
effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast
cancer should be considered.
Aminoglutethimide is a drug successfully used for endocrine
treatment of breast cancer (Santen, 1986). It is thought to
act by inhibiting oestrogen production in post-menopausal
women. The major oestrogen production pathway in non-
menstruating women is peripheral conversion of A4-
androstenedione into oestrone (Grodin et al., 1973), and
aminoglutethimide is thought to act through an efficient
inhibition of the aromatase enzyme (Thompson & Siiteri,
1974). In vivo investigations have shown oestrone production
from androstenedione to be inhibited by 95% in patients on
aminoglutethimide treatment (Santen el al., 1978). However,
patients receiving aminoglutethimide treatment seem to have
sustained oestradiol as well as oestrone plasma levels about
50% of their pretreatment values (Dowsett et al., 1985;
Harris et al., 1983; Newsome et al., 1978; Santen et al., 1982;
Vermeulen et al., 1983). The possibility that oestrogens may
be produced by pathways other than aromatisation of
androstenedione has been suggested (Kirschner et al., 1978;
Longcope et al., 1982; Reed et al., 1986). The question
whether it is possible to inhibit oestrogen production com-
pletely by aromatase inhibition remains open.
Aminoglutethimide is a potent inducer of certain hepatic
mixed function oxydases, increasing the metabolism of
several drugs in man (L0nning et al., 1984, 1986). In
previous studies we found aminoglutethimide to stimulate
the metabolism of oestrone sulphate (L0nning et al., 1987)
and increase urinary excretion of oestrogen metabolites
produced by mixed function oxidations (L0nning & Skul-
stad, 1989). It has been suggested that oestrone sulphate is
an important precursor of intracellular oestradiol (Santner et
al., 1984, 1986), an increased metabolism of this oestrogen
might reduce tumour oestrogen exposition.
The present study was initiated to measure plasma
oestrone and oestrone sulphate production rate in patients
receiving aminoglutethimide treatment to evaluate (1) the
reduction in oestrone and oestrone sulphate production rate,
and (2) to what extent aminoglutethimide influences plasma
oestrone and oestrone sulphate by stimulating oestrogen
metabolism.
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Patients, material and methods
Patients
Nine post-menopausal women receiving aminoglutethimide
therapy for advanced breast cancer were studied. Their mean
age was 61.7 years (range 52-73 years), their mean body
weight was 68.7kg (range 49-109kg). Patient H.S. was a
smoker of 10 cigarettes a day, the others were non-smokers.
Except for patient S.P., who received cimetidine when inves-
tigated on AG treatment, no patient received concomitant
drugs known to interfere with drug or steroid metabolism.
Patients L.M. and A.L. had been treated with ovarian
irradiation, the rest having had a spontaneous menopause.
All patients had received previous tamoxifen treatment.
Six patients had tamoxifen as their last treatment before
aminoglutethimide, the other three patients had received
treatment with medroxyprogesterone acetate before com-
mencing aminoglutethimide treatment. None of the patients
had received previous chemotherapy. Time from terminating
other endocrine treatment before commencing on amino-
glutethimide was between 16 and 77 days.
Aminoglutethirnide treatment
All patients received a common drug schedule of aminoglute-
thimide (Orimeten, Ciba-Geigy) 250mg q.i.d. with cortisone
acetate (50mg b.i.d. for two weeks, than 25mg b.i.d.) as
described elsewhere (Kvinnsland et al., 1984). No modifi-
cation of therapeutic regimen was done because of this
investigation.
Reagents
All solvents were of analytical or spectrophotometnrc grade
and obtained from Merck AG (Darmstadt, FR Germany),
except for diethyl ether (Den Norske Eterfabrikk, Oslo,
Norway). Unlabelled oestrogens were obtained from Sigma
Chemical Company (St Louis, USA). 2,4,6,7 3H-oestrone
(85105-Cimmol-1), 414C-oestrone (50-60mCimmol- ) and
6,73H-oestrone sulphate (40-60Cimmol-') were obtained
from New England Nuclear Corp. (Dreiech, FR Germany).
3H-oestrone was purified on an LH-20 Sephadex column
before use to obtain a purity greater than 97%. 3H-oestrone
sulphate was extracted with diethyl ether to remove free
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steroids, and a purity greater than 97% was found by
chromatography after hydrolysis. The purity of 4 14C-
oestrone was more than 98% at delivery.
Investigation protocol
The study was approved by the regional ethical committee.
All patients gave their informed consent to participate.
Six patients received tracer bolus injections of 20pCi
4'4C oestrone and 70pCi of 6,73H-oestrone sulphate
(Table I). The steroids were dissolved in 21 ml saline:ethanol
(95/5w/w) immediately before use. Twenty millilitre was
injected. From the residual, 50y1 samples were obtained for
liquid scintillation counting.
Three patients (B.V., S.P. and K.M.) had oestrone sul-
phate clearance during aminoglutethimide and in a control
situation measured in a previous investigation (Lonning et
al., 1987). These patients had blood samples obtained on the
morning of their steroid injections, from which plasma
oestrogens could be measured, and the oestrone sulphate
production rate could be calculated.
All patients except S.P., K.M. and L.M. received a bolus
injection before and a second injection following 3-21 weeks
on aminoglutethimide treatment. The three patients men-
tioned above were relapsing following 5-8 months on amino-
glutethimide treatment. They received a first injection when
still on aminoglutethimide therapy, and a second control
injection 3-9 weeks following cessation of aminoglutethimide
therapy. The one patient (L.M.) who received her secoind
injection 9 weeks following withdrawal of aminoglutethimide
therapy was then receiving doxorubicin 20mg weekly (Gun-
dersen et al., 1986).
The steroid injection technique, the blood sampling proto-
col and the labelled oestrogen analysis were as described
previously (L0nning et al., 1987). Blood samples (20ml) were
drawn at 8 a.m. for plasma oestrone and oestrone sulphate
determination. The patients then received their tracer oestro-
gens as a min bolus injection, and heparinised blood
samples (10ml) were drawn through an indwelling needle at
5, 10, 15, 22.5, 30, 45, 60, 90, 120, 150, 180, 210, 240, 300,
360, 480, 600, 720 and 900min. All samples were centri-
fuged, plasma separated and stored at -20°C until analysis.
Oestrogen measurement
Plasma oestrone, plasma oestrone sulphate and plasma
tracer oestrogen concentrations were measured by methods
previously descnrbed (Lonning et al., 1987, 1989). Samples
from each patient were analysed in the same batch. The
intra-assay coefficients of variation for radiolabelled oestrone
and oestrone sulphate were 6.9% and 8.5% respectively. For
plasma oestrogen analysis, intra/inter assay coefficients of
variation for oestrone and oestrone sulphate were 8/12%
and 7/9% respectively.
Measurement ofaminoglutethimnide in serum
Serum obtained 3 and 12h following tracer injections were
analysed for aminoglutethimide. The mean value of these
two determinations were interpreted as a steady state serum
level. Aminoglutethimide was determined by the method of
Schanche et al. (1984).
The three patients (B.V., S.P. and K.M.) who had their
oestrone sulphate clearance determined previously were
found to have aminoglutethimide plasma levels in the
normal range for patients on steady state treatment with that
drug schedule (Lonning et al., 1985, 1987).
Pharmacokinetic calculations
The metabolic clearance rate of oestrone and oestone sul-
phate were calculated from the equation:
Cl =dose/AUC
where dose is the amount of the respective tracer adminis-
tered and AUC the area under its elimination curve.
In a previous study, we found that oestradiol kinetics
could be well fitted to a 3-compartmental model, while the
kinetics of oestrone sulphate did not fit into a simple 2- or 3-
compartment open model, most probably because of its
enterohepatic circulation (L0nning et al., 1987). Therefore,
oestrone sulphate AUC was determined by the trapezoidal
rule, adding the residual by extrapolation to infinity. The
same technique was applied in this investigation. Similar to
what has been found by others (Longcope et al., 1974) the
oestrone elimination curves in this study were found to be
well fitted to a 3-ompartmental open model (curve-fitting
performed by Statgraphics on an IBM PC 5060). AUC for
oestrone was calculated as the integral of the elimination
curve. For comparison, it was also calculated by use of the
trapezoid rule.
Oestrone and oestrone sulphate production rate (PR) were
calculated as:
PR=plasma concxCl (Gurpide et al., 1963)
where plasma conc is the endogenous plasma oestrogen
concentration before tracer injection, and Cl is the blood
clearance rate of the respective oestrogens.
The transfer factors fmO,no,,s (amount of 14C-oestrone
administered, which appears in plasma as 14C-oestrone sul-
phate) and finots-o, (the amount of 3H-oestrone sulphate
administered which appears in plasma as 3H-oestrone) was
calculated according to the equation (Rowland & Tozer,
1980):
fm= - (Cl.Ob.it xAUCU...C) (C;t. _ dxAUC,., co,d)
The amount of oestrone sulphate produced from circulating
oestrone (Oe1SPRo,) was calculated as:
Oe1SPRO.,=OelPR xfmn5ocs
Results
The mean ratio between oestrone AUC calculated by the
integral and trapezoid methods was 0.98+0.11 (s.d.) showing
a good agreement. Only the clearance values calculated from
the integral AUC are reported.
An example of radioactive plasma oestrogen concent-
0 1
D
a
o 0
-0
0 0
C) 0
UI
0.01
0.001
0 0001
10 15
Time (h)
Fure 1 Plasma concentration of 1'4C-oestrone (0),
"4C-oestrone sulphate (-) and 3H-oestrone sulphate (OI) in a
patient (RS.) following a bolus injection of tracer oestrogens
before commncng on aminoglutethimide treatmentAMINOGLUTETHIMIDE INFLUENCE ON OESTROGEN DISPOSMON 109
Table I Oestrone plasma concentration (0e1 conc), oestrone plasma clearance
(Oe1 C1) and oestrone production rate (Oe1 PR) measured in 5 patients before and
dunrng aminoglutethimide treatment and in one patient (L-M.) on aminoglutethimide
treatment and 6 weeks following cessation of therapy
Control situation On aminoglutethimide treatment
Oe1 conc. Oel Cl Oe, PR Oel conc. Oel Cl Oel PR
Patient (pM) (lh-1) (nmolh-1) (pM) (lh-1) (nmolh- 1)
H.A. 133.0 51.6 6.86 80.0 63.2 5.06
A-L. 104.0 56.3 5.86 48.0 79.6 3.82
R.S. 68.5 593 4.06 37.1 82.9 3.08
S.M. 139.1 61.8 8.60 55.0 66.6 3.66
H.S. 126.3 34.2 4.32 102.7 36.3 3.73
LM. 90.3 29.2 2.64 40.4 47.3 1.91
Mean 110.2 48.7 5.39 60.5 62.7 3.54
Mean 0 alteration -45.7% +29.9% -30.7,o
P <0.05 <0.05 <0.05
Table II Oestrone sulphate plasma concentration (Oe1Sconc), oestrone sulphate
plasma clearance (Oe1SCI) and oestrone sulphate production rate (Oe1SPR) mea-
sured in si patents before and during aminoglutethimide treatment and in three
patients (S.P, K-M. and LM.) on aminoglutethimide treatment and 3-6 weeks
following cessation of aminoglutethimide therapy
Control situation
Oe1Sconc.
Patient (PM)
B.V. 624
S.P. 340
K.M. 530
H.A 883
A.L. 826
R-S. 868
S.M. 710
H.S. 744
L.M. 808
Mean 704
Mean 0 alteration
p
Oe1SCl
(lh-1)
6.3
6.6
4.3
4.4
6.4
3.4
7.4
6.3
2.9
5.3
Oe1SPR
(nmolh- 1)
3.93
2.24
2.28
3.89
5.28
2.96
5.26
4.68
2.36
3.65
On aminoglutethimide treatment
Oe,Sconc. Oe1SCI Oe1SPR
(PM) (lh-1) (nmolh-1)
185
118
195
330
154
184
240
232
120
195
-713%h
<0.005
14.5
7.9
9.4
9.1
14.2
9.5
17.8
9.3
7.0
11.0
+1 11.8°o
<0.005
2.68
0.94
1.83
3.01
2.20
1.74
428
2.16
0.84
2.19
-41.005
<e-0.005,
Table III Fraction of oestrone metabolised into oestrone sulphate (fin1), fraction of oestrone sulphate
metabolised into oestrone (fm2), amount of oestrone sulphate produced by conjugation of circulating
oestrone (E1SPR°') and ratio of total plasma oestrone sulphate calculated to be produced from
circulating oestrone (Oe1SPR°'/Oe1PR) in the same group of patients as described in Table I
Control situation Onaminoglutethimide treatment
OeiSPR°'- OeISPR°'e OeiSPR)e1 Oe1SPR°L
Patient fin, fin2 (nmolh 1) Oe1SPR fin, fin2 (nmolh ') Oe1SPR
H.A. 0.77 0.18 5.28 1.36 0.77 0.12 3.90 1.29
A-L. 0.71 0.24 4.16 0.79 0.53 0.11 2.02 0.92
R-S. 0.91 0.45 3.69 1.25 0.76 0.21 2.28 1.31
S.M. 0.67 0.18 5.76 1.10 0.50 0.09 1.83 0.43
H.S. 0.84 0.36 3.62 0.78 0.58 0.09 2.13 0.99
L.M. 0.82 0.38 2.16 0.12 0.83 0.20 1.59 1.89
Mean 0.79 0.30 4.11 1.03 0.66 0.14 2.29 1.14
Mean 0 alteration -16%o -5r0 -4r, + 1500
P ns. <0.05 <0.05 n.s.
rations following a bolus injection is shown in Figure 1
(patient R.S., investigated before aminoglutethimide ther-
apy). Oestrogen disposition parameters in patients during
aminoglutethimide treatment and in their control situation
are given in Tables I-III. The results are summarised as
follows: (1) Aminoglutethimide treatment reduces plasma
oestrone and oestrone sulphate levels by a mean of 45.7%
and 71.3% respectively (P<0.05 and P<0.005). (2) The
blood production rates of oestrone and oestrone sulphate are
consistently reduced by 30.7% and 41% respectively
(P<0.05 and P<0.005). Similarly, the amount of oestrone
sulphate produced from oestrone is reduced by a mean of
42% (P<0.05). (3) The discrepancy between the reduction in
plasma level and production rate for oestrone as well as
oestrone sulphate is caused by alterations in the metabolic
clearance rates for both oestrogens due to aminoglutethimide
treatment. The clearance rate of oestrone is consistently
increased by a mean of 29.9% (P<0.05), while the clearance
rate of oestrone sulphate is increased by a mean of 111.8%
(P<0.005). (4) A consistent (mean 52%) reduction in the
fraction of oestrone sulphate converted to circulating oes-
trone is seen (P<0.05).
The plasma level of aminoglutethimide during steady state
treatment was between 3.5 and 12.3pgmPl'. No correlation
between individual plasma aminoglutethimide levels and
alterations in oestrogen disposition was seen.110 P.E. L0NNING et al.
Plasma levels of oestrone and oestrone sulphate were simiilar
to values reported by others (Harris et al., 1984; Roberts et
al., 1980; Samojlik et al., 1977; Vermeulen et al., 1978). The
clearance and production rates for oestrone in our patients
were in the lower range. but consistent with results reported
previously for breast cancer patients and normal post-
menopausal women (Judd et al., 1982; Kirschner et al., 1978;
Longcope & Williams, 1974; Reed et al., 1986). The plasma
clearance of oestrone sulphate was similar to values found
by us in a previous investigation (L0nm'ng et al., 1987), the
oestrone sulphate production rate was found somewhat
lower than values reported for young men and menstruating
women in the follicular phase of cyclus (Longcope, 1972;
Ruder et al., 1972). The transfer constants for oestrone into
oestrone sulphate (fmtoIls) and oestrone sulphate into
oestrone (fm0,,sck) were in the upper range compared to
values reported for younger subjects (Longcope. 1972; Ruder
et al., 1972).
The finding that the amount of oestrone sulphate pro-
duced from oestrone (Oe1SPR0,) might exceed the total
amount of oestrone sulphate produced (Oe1SPR) might be
confusing. However, plasma oestrogen levels used for calcu-
lating production rate were measured in single samples
obtained at 8 a.m. Oestrone sulphate, having a half-life of
about 6h does not show diurnal cycle variations (Noel et al.,
1979). One study has suggested a diurnal variation of
oestrone in men (Baird & Guevara, 1969). While we have not
been able to reproduce this finding in post-menopausal women
(Dowsett & L0nning, unpublished results), in some patients
a considerable variation in the plasma level during the day
may be seen. Therefore, while the oestrone sulphate produc-
tion rate should be expected to vary little dunrng the day,
larger variations in the oestrone plasma levels and therefore
the Oe PR as well as the Oe1SPRoe may be anticipated.
Our findings support previous results in the literature
suggesting that oestrone sulphate is produced by conjugation
of circulating oestrone and oestradiol only (Longcope, 1972;
Ruder et al., 1972).
In this study we found aminoglutethimide treatment to
depress plasma oestrone and oestrone sulphate to about 55%
and 30% of their control levels. consistent with previous
findings by us (L0nning et al., 1989) and others (Harris et
al., 1983; Santen et al., 1982; Vermeulen et al., 1983). The
finding that aminoglutethimide treatment causes a 112%
increase in the metabolic clearance rate of oestrone sulphate
is similar to our previous findings (L0nning et al., 1987).
The clearance rate of oestrone during aminoglutethimide
treatment was reported by Santen et al. (1978) to be
unaffected by aminoglutethimide treatment. In contrast, in
this investigation we found oestrone clearance rate to be
consistently increased to a moderate extent. Due to a small
number of patients in both studies any difference may have
occurred by chance. However, it may also be explained by
different protocols of investigation. While we used a bolus
injection method. Santen and co-workers applied a 4h
steady state infusion technique (Santen et al., 1978). As
oestrone sulphate has a half-life about 6h, there may be
doubts whether oestrone steady state levels are reached by
such short-term infusions (Hembree et al., 1969). As amino-
glutethimide treatment increases the metabolic clearance rate
and shortens the half-life of oestrone sulphate, plasma steady
state levels for oestrone and oestrone sulphate may be
achieved quicker when such infusions are done in patients on
aminoglutethimide treatment compared to the control situa-
tion. Accordingly, such a flaw could mask a moderate
increase in plasma oestrone clearance caused by aminoglute-
thimide treatment.
An explanation why aminoglutethimide treatment
increases the metabolic clearance rate of oestrone sulphate
but not oestradiol has been discussed in detail previously
(L0nning et al., 1987; L0nning & Kvinnsland, 1988). The
discrepancy may be due to a different metabolic clearance
rate of the two oestrogens. Oestradiol is a so-called 'highly
extracted compound' (Wilkinson & Shand, 1975) with a
clearance rate exceeding hepatic plasma flow (Longcope et
al., 1968). Therefore, stimulation of its metabolic enzymes
may have little impact on oestradiol plasma clearance rate.
Oestrone sulphate is a 'low extracted compound' with a
clearance rate about 5-1Olh-l- If oestrone sulphate metabo-
lising enzymes are stimulated, this may result in an increased
plasma clearance rate of this oestrogen. As the clearance rate
for oestrone is even higher than the clearance rate for
oestradiol (Longcope & Williams, 1974), it may be surprising
to find that oestrone clearance rate is increased by amino-
glutethimide treatment. However, an explanation may be
found in the reduced conversion of oestrone sulphate back
to oestrone (fmo,,s<o1,). While 1-2% of circulating oestrone
sulphate will be converted into plasma oestradiol (Ruder et
al., 1972), 18-45% of circulating oestrone sulphate was
converted into plasma oestrone in our patients. Therefore. a
considerable amount of oestrone converted into oestrone
sulphate will be reconverted into plasma oestrone. In a
previous investigation we found the fraction of oestradiol
converted into oestrone sulphate to be reduced by amino-
glutethimide treatment (L0nning et al., 1987). In this investi-
gation we found aminoglutethimide to reduce the fraction of
oestrone converted into plasma oestrone sulphate as well as
the fraction of oestrone sulphate converted into plasma
oestrone. These findings are probably due to an increased
intracellular metabolism of oestrogens (Lonning &
Kvinnsland, 1988). An increased metabolic clearance rate of
oestrone sulphate with a reduced conversion of oestrone
sulphate to oestrone may result in an increase in plasma
oestrone clearance rate.
A moderate reduction in the production rate of oestrone
and oestrone sulphate of 30.7% and 41.0% contrasts with
previous findings of a 95% inhibition of the aromatase
reaction (Santen et al., 1978). However, in recent years the
hypothesis that post-menopausal oestrogen production does
occur by peripheral aromatisation of androstenedione only
has been challenged (Kirschner et al., 1978: Longcope et
al., 1982; Reed et al., 1986). Our results indirectly support a
theory that oestrogen production pathways other than the
aromatisation of androstenedione into oestrone may be
intact in patients receiving aminoglutethimide treatment.
The findings in this paper focus on the mechanism of
action of aminoglutethimide in the treatment of breast
cancer. The successful use of this drug for breast cancer
treatment has prompted the development of new aromatase
inhibitors undergoing current investigations (Goss et al.,
1986). It has been a concept for 10 years that aminoglute-
thimide depresses plasma oestrogens by inhibiting the peri-
pheral production of oestrone from androstenedione only
Santen et al., 1978). Obviously, any other mechanism by
which aminoglutethimide may depress plasma oestrogens
could be part of its mechanism of action.
Recently, we reported that aminoglutethimide stimulates
oestrone sulphate metabolism (L0nning et al., 1987)
and reduces the plasma oestrone sulphate oestrone ratio
(L0nning et al., 1989). If plasma oestrone sulphate is an
important oestrogen source for breast tumours, an increased
metabolism of this oestrogen may be of importance for the
mechanism of action of aminoglutethimide. The results of
this study suggest that stimulation of oestrone sulphate
metabolism may be of equal importance to inhibition of the
production rate as a mechanism lowering plasma oestrone
sulphate levels. Also, it suggests that the same mechanism
may contribute to plasma oestrone depression. Accordingly,
our results question aromatase inhibition as the sole mecha-
nism of action of aminoglutethimide.
The findings of this study also suggest that aminoglute-
thimide treatment does not cause a complete inhibition of
post-menopausal oestrogen production, probably due to the
existence of alternative production pathways not inhibited byAMINOGLUTETHIMIDE INFLUENCE ON OESTROGEN DISPOSMON ill
this drug. Further studies on aromatase inhibitors should
consider the total production rate of oestrogens as well as
aromatase inhibition, to evaluate any possible influence of
drug treatment on oestrogen disposition.
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